A senior investment professional and corporate director with experience across private equity, M&A and corporate finance, Daniel L. Lippincott combines operational oversight with capital-allocation discipline. He frequently sits on boards to guide growth strategies, balance-sheet optimization and exit planning for mid-market companies. Market relevance stems from expertise in deal execution, restructuring and shareholder value creation, with a track record of working alongside management teams and limited partners to scale businesses and realize liquidity events.
A senior investment professional and corporate director with experience across private equity, M&A and corporate finance, Daniel L. Lippincott combines operational oversight with capital-allocation discipline. He frequently sits on boards to guide growth strategies, balance-sheet optimization and exit planning for mid-market companies. Market relevance stems from expertise in deal execution, restructuring and shareholder value creation, with a track record of working alongside management teams and limited partners to scale businesses and realize liquidity events.
Centers on active, value‑oriented private equity investing in mid‑market companies, blending operational oversight with disciplined capital allocation. Prefers control or board‑level positions to drive growth, restructure underperformers, optimize balance sheets and prepare for liquidity events over a multi‑year horizon. Underwrites deals for cash‑flow resilience, prudent leverage and clear exit pathways, aligning incentives with management and limited partners to convert strategic improvements into measurable shareholder value.
Centers on active, value‑oriented private equity investing in mid‑market companies, blending operational oversight with disciplined capital allocation. Prefers control or board‑level positions to drive growth, restructure underperformers, optimize balance sheets and prepare for liquidity events over a multi‑year horizon. Underwrites deals for cash‑flow resilience, prudent leverage and clear exit pathways, aligning incentives with management and limited partners to convert strategic improvements into measurable shareholder value.
| Trades 13899 | Longs Won 9267/13899 66% | Profit Factor 2.88 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $1.09M |
| Average Win $253,697.78 | Best Trade (Aug 24) $77.47M | Sharpe Ratio -382.19 |
| Average Loss -$176,016.7 | Worst Trade (Dec 31) -$37.91M | Z-Score -17.95 (100%) |
| Commissions $0 | Avg. Trade Length 1y 8m 1w 3d | Expectancy $110,419.75 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 20,000 | 18,000 | 16,000 | 14,000 | 12,000 | 10,000 | 8,000 | 6,000 | 4,000 | 2,000 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AACIU Armada Acquisition Corp. III | 253,925 | $2.65M | $2.57M | - | -$74,653.95 | -2.82% | 0.0 |
AACP Apogee Acquisition Corp | 2.65M | $26.35M | $26.56M | - | $211,846.26 | 0.8% | 0.0 |
ABBV AbbVie Inc. | 1,050 | $243,117 | $261,933.01 | - | $18,816.01 | 7.74% | -0.542% |
ACGC ACP Holdings Acquisition Corp. | 1.35M | $13.41M | $13.49M | - | $80,916.96 | 0.6% | 0.0 |
ACWX ISHARES MSCI ACWI EX U.S. ETF | 4,590 | $255,204.29 | $357,423.3 | - | $102,219.01 | 40.05% | -0.051% |
ADAC Adama Technologies Corp. | 22,000 | $217,800 | $222,200 | - | $4,400 | 2.02% | 0.0 |
AFB AllianceBernstein National Municipal Income Fund | 3.6M | $41.11M | $40.03M | - | -$1.08M | -2.63% | +0.817% |
AFJK Aimei Health Technology Co., Ltd. | 77,125 | $788,581.53 | $940,925 | - | $152,343.47 | 19.32% | +1.667% |
AGG iShares Core U.S. Aggregate Bond ETF | 3,385 | $338,733.76 | $329,969.8 | - | -$8,763.96 | -2.59% | -0.215% |
AIIA AI Infrastructure Acquisition Corp. | 2.01M | $20.15M | $20.56M | - | $411,855.04 | 2.04% | +0.323% |
AIO Virtus Artificial Intelligence & Technology Opportunities Fund | 324,291 | $7.81M | $8.62M | - | $803,152.88 | 10.28% | -0.673% |
ALIS Calisa Acquisition Corp | 473,675 | $4.73M | $4.83M | - | $104,208.5 | 2.2% | +0.098% |
AMGN Amgen Inc. | 680 | $239,258 | $282,342.79 | - | $43,084.79 | 18.01% | -0.629% |
ANSC Agriculture & Natural Solutions Inc. | 1.61M | $17.08M | $18.5M | - | $1.41M | 8.27% | 0.0 |
| APAC APAC | 465,125 | $4.67M | $4.67M | - | -$4,420.44 | -0.09% | 0.0 |
| APXT APXT | 1.25M | $12.47M | $12.46M | - | -$9,899.97 | -0.08% | 0.0 |
APXTU Apex Treasury Corporation Units | 44,051 | $444,474.59 | $444,474.59 | - | - | - | 0.0 |
ARCL ARC Group Acquisition I Corp. | 247,600 | $2.45M | $2.47M | - | $19,808 | 0.81% | 0.0 |
| ARTC ARTC | 973,200 | $9.66M | $9.66M | - | - | - | 0.0 |
ASG Liberty All-Star Growth Fund, Inc. | 4.55M | $23.94M | $24.88M | - | $940,113.52 | 3.93% | -0.182% |